Reaktionsgleichung
ClC1C=CC(NC([C:11]2[S:19][C:18]3[CH2:17][CH:16]([C:20]([OH:22])=O)[NH:15][CH2:14][C:13]=3[CH:12]=2)=O)=CC=1.[CH3:23][N:24]1[CH2:28][CH2:27][N:26]=[C:25]1[C:29]1[CH:34]=[CH:33][C:32]([NH2:35])=[CH:31][CH:30]=1.[CH2:36]([Cl:39])[CH2:37]Cl.[OH2:40]>CN(C=O)C>[CH3:23][N:24]1[CH2:28][CH2:27][N:26]=[C:25]1[C:29]1[CH:34]=[CH:33][C:32]([NH:35][C:20]([CH:16]2[N:15]([C:14]([NH:15][C:16]3[CH:20]=[CH:37][C:36]([Cl:39])=[CH:18][CH:17]=3)=[O:40])[CH2:14][C:13]3[CH:12]=[CH:11][S:19][C:18]=3[CH2:17]2)=[O:22])=[CH:31][CH:30]=1Komponenten
6
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
To a solution of 5N-(4-chlorophenylaminocarbonyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-6-carboxylic acid (40 mg, 0.12 mmol) and 4-(1-Methyl-4,5-dihydro-1H-imidazol-2-yl)-phenylamine (42 mg, 0.24 mmol) in DMF (3 mL) and H2O (0.5 mL) at room temperature, EDC (68 mg, 0.35 mmol) was added. The mixture was stirred at room temperature overnight. It was concentrated in vacuo. The residue was purified by HPLC to give the titled compound as a powder (25 mg). MS 494.3 and 496.3 (M+H, Cl pattern).
Aufarbeitung
- concentrationIt was concentrated in vacuo
- customThe residue was purified by HPLC
Quellen und Nachweise
- ORD-Eintrag
- ord-cfea6a67daa64563ab23c6c906a058a3
- Quelldatensatz
- uspto-grants-2009_11
- Patentnummer
- US07612089B2
Verknüpfte Notizen
Wird geladen…